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The purpose of this document is to provide a model process and procedures that can be used as 
starting point for implementation of clinical trials using Exception from Informed Consent for 
Emergency Research (EFIC) in NIH funded multicenter clinical trials.  The process and procedures 
described can and must be adapted to the specific needs and details of any future trials.  The 
materials provided were developed and informed by both thorough review of the accumulated 
scholarship related to EFIC, and other lessons learned through practical shared experiences of prior 
NIH funded emergency care researchers.   
This document is intended to be a useful, practical, and tested peer-to-peer tool for future 
investigators in this field.  It is not intended to be a definitive guideline for application of the EFIC 
regulations, and should NOT be interpreted as any form of regulatory guidance.  Regulatory guidance 
is available from FDA.  This document does not represent the only way to implement Exception from 
Informed Consent, and may not be applicable or optimal for EFIC studies that differ from those for 
which this document was created.  This document is intended to be open access, and shared through 
a Creative Commons Attribution-NonCommercial (CC BY-NC) license that lets others adapt, and 
build upon the work non-commercially.  New works must acknowledge the source materials and the 
NIH and be non-commercial. The derivative works do not have be licensed on the same terms. 
Background 
Planned emergency research involving clinical trials in which critically ill or injured patients are unable 
to express a desire to consent to or decline participation are necessary for the advancement of acute 
life-saving medical care.  United States regulations allow an exception from the requirement for 
informed consent (EFIC) for certain clinical trials.  Prior to the passage of these regulations in 1996 
(21 CFR 50.24), there was no clear regulatory provision to allow clinical trials in emergency settings 
where consent is impracticable.  The EFIC regulations contain a number of important provisions.  
Most obviously, they require that it be impracticable to conduct the proposed trial by only enrolling 
individuals who can provided informed consent or who have a legally authorized representative 
(LAR).  In addition, the regulations require a prospect of direct benefit for enrolled subjects, and limit 
the use of EFIC to life-threatening conditions for which existing therapy is unsatisfactory or unproven, 
and in which there is a short therapeutic window for the proposed intervention.  They are also notable 
for requiring two forms of community engagement; community consultation prior to approval and 
initiation of a study; and public notification or disclosure prior to and after the study.   
In the more than 20 years since passage of the EFIC regulations, investigators, IRBs, and regulators 
have gained substantial experience interpreting and implementing this regulatory structure.  
Determining precisely which studies qualify for EFIC, what constitutes an “unsatisfactory or unproven” 
standard of care, and what constitutes impracticability of informed consent can all be difficult.  
Implementation of EFIC can be especially intimidating for investigators and IRBs who lack experience 
with this kind of research.  The recent single IRB review requirements in NIH clinical trials policy, and 
in the revised Common Rule, creates additional unprecedented challenges to EFIC trials and review 
of community engagement.  Single IRB review, however, also offers an opportunity to consolidate 
experience with EFIC and build better, more consistent, and equitable processes.  
 
 
Organization of this document 
This document is organized into three model procedures or process statements.  These sub-
documents are examples developed for specific prior EFIC clinical trials performed in NIH funded 
clinical trial networks.  The documents contain language and details that may be specific to a single 
NIH funded clinical trial network, and a sample trial of patients with traumatic brain injury, but that are 
illustrative of approach and method that can be used for most other types of planned emergency 
research with EFIC in any NIH funded infrastructure.   
For each document, the body of the text (presented in black font) can be considered an example to 
be modified and individualized for future use.  Care should be taken in cutting and pasting.  Each 
EFIC study is unique with particular needs that should be carefully considered.  More generalized 
commentary, explanation, and instruction is provided in blue font in wide margins notes. 
The three sub-documents include the following: 
A. Investigator’s EFIC Implementation Plan 
This is the longest part of the document.  It describes the plan for a single clinical trial created by 
investigators and submitted to the single IRB, that describes why the trial meets the criteria for 
EFIC, lays out the principles that guide the investigators’ approach to implementation, and 
proposes a specific menu for the kinds of community consultation and public disclosure activities 
that will be conducted.  The plan also summarizes how results of those activities will be reported 
back to the IRB.  
B. Standard Operating Procedure for Trial Applications involving Exception from Informed 
Consent (EFIC) to a Single/Central Institutional Review Board 
This SOP describes the general workflow developed by a clinical trial network and a partnering 
single or central IRB.  The strategy is intended to organize and streamline the many steps 
required in sequence to properly and efficiently review, consider, and approve (or reject) an EFIC 
protocol application, and subsequent enrollment site applications to the IRB.  It can serve as a 
template for an SOP for either a trial coordinating center or an IRB. 
C. Guidelines for Centralized Review of Community Consultation and Public Disclosure 
The last document provides a sample of the kind of guidance that an IRB might adopt internally to 
help a board create a cohesive approach to EFIC reviews.  It discusses elements of review, 
management of deliberations, and types of board actions.  It is intended to provide IRB leadership 
and board members with a common platform from which to work, and around which board 
education and training might be organized. 
Supplemental Material:  Sample Site EFIC Activity Reports for IRB Submission 
The three subdocuments and the supplemental material are meant to be complementary.  They are 
intended to be useful and practical examples and strategies for implementation.  As noted previously, 
they are not intended to be binding or definitive guidelines or interpretations of the EFIC regulations, 
and should not be considered as regulatory guidance. 
 
 
A. Investigator’s EFIC Implementation Plan 
 
INTRODUCTION 
The goal of this plan is to describe the implementation of the 
protections associated with 21 CFR 50.24, Exception from Informed 
Consent (EFIC) Requirements for Emergency Research in a specific 
clinical trial.  Implementation of this plan is the first phase of 
conducting the proposed trial.  The findings acquired from planned 
activities will be presented to the Central IRB (CIRB) to help the IRB 
assess community attitudes related to the study.  
Research involving the acute care of patients with emergencies such 
as severe Traumatic Brain Injury (TBI) presents ethical challenges. 
Respecting participants and their autonomy through the informed 
consent process is a cornerstone of ethical research, but patients with 
severe TBI are comatose and unable to participate in an informed 
consent process. When available a legally authorized representative 
(LAR) may act as a surrogate decision maker for a comatose patient. 
The LAR can decide if the patient will participate in the research study, 
even though the wishes of the patient may not be known. However, for 
many patients with severe TBI, no LAR is readily available during the 
patient’s resuscitation and emergency care.  Excluding patients 
without capacity or an available LAR from TBI research does not 
necessarily defend patient autonomy since the patient’s actual wishes 
are unknown.  In fact, when they can be asked, patients and their 
representatives choose to participate more often than not. Excluding 
patients without capacity, however, limits the ability to ever 
scientifically improve care, and makes enrollment in the emergency 
setting impracticable. Therefore, this study will enroll participants for 
whom an LAR is unavailable with EFIC. 
 
OVERVIEW 
All patients meeting eligibility criteria for this trial will be obtunded or 
comatose and unable to give informed consent to participate.  
Participants will be enrolled in this trial either with the informed 
consent of a LAR or with exception from informed consent (EFIC) for 
emergency research under the conditions established at 21CFR50.24 
and pursuant to 45CFR46.101(i) and the HHS Secretarial Waiver at 
FR Doc. 96–24968.   
Upon hospital arrival of a potentially eligible subject, study teams will 
diligently attempt to determine the patient's identity and the availability 
This “Investigator’s EFIC 
Implementation Plan” is a 
sample procedure based 
upon a trial enrolling 
participants with acute 
severe traumatic brain 
injury (TBI).  This is 
intended to be used as a 
model or template for 
trials involving patients 
with any qualifying 
emergency condition.  For 
trials involving patients 
with other conditions, the 
elements in this example 
that refer to TBI must be 
modified as appropriate 
to the clinical trial for 
which this is being 
adapted.  The plan also 
sometimes refers to 
specific elements of the 
sample trial’s protocol, 
which should also be 
disregarded when 
adapting this procedure 
for a future trial. 
The implementation plan 
is where the investigators 
explain their plan for 
conducting EFIC. It is part 
of the proposal reviewed 
by regulators and is a 
roadmap to educate 
participating sites. 
 
The INTRODUCTION and 
OVERVIEW lay out the 
anticipated use of EFIC 
and informed consent in 
the trial.   
 
 
of an LAR.  If an LAR is available at any time prior to the routine 
emergent placement of intracranial probes for standard clinical 
management of severe TBI, the patient may only be enrolled with 
prospective informed consent from the LAR, as documented by a 
signed informed consent document.  If an LAR is not available prior to 
the routine emergent placement of intracranial probes, eligible patients 
will be enrolled with EFIC.  When enrolling with EFIC, enrollment and 
randomization take place immediately after probe placement.  
Subsequent to an EFIC enrollment, attempts will be made to notify an 
LAR at the earliest opportunity, and consent to continue in the study 
will be sought.   
Enrollment with Consent 
If an LAR is available prior to the routine emergent placement of 
intracranial probes, the patient will only be enrolled with the 
prospective informed consent of the LAR.  Informed consent is a 
process involving a meaningful and compassionate exchange of 
information, questions, and answers between an LAR and a study 
team member delegated to obtain informed consent.  The study team 
member will discuss the opportunity to participate in a balanced and 
fair manner and will review the informed consent document with the 
LAR. The informed consent document provides a record of the 
informed consent process. The LAR signature on the consent 
document indicates permission for the patient’s participation and 
acknowledges this consent.   
Enrollment with EFIC 
Upon hospital arrival of a potentially eligible subject, study teams will 
diligently try to determine the patient's identity and the availability of an 
LAR.  Both routine hospital and study team resources and processes 
should contribute to these efforts. The steps undertaken to identify the 
patient and find the LAR should be documented on the informed 
consent log case report form.  If an LAR is not available prior to the 
routine emergent placement of intracranial probes, eligible subjects 
will be enrolled with EFIC.  After EFIC enrollment, efforts to contact an 
LAR will continue.  Once the LAR is available and as soon as it is 
feasible, the LAR will be informed of the subject’s enrollment in the 
study.  Details of the study, the potential risks and potential benefits of 
participating in the study will be explained to the LAR.  After 
discussing the study with the LAR, the LAR will be given the option of 
allowing the subject to continue study participation, or to withdraw 
from the study.  The LAR will be informed that the decision to continue 
participation in the study may be withdrawn at any time throughout the 
An important element 
that will differ between 
EFIC clinical trials is 
whether the investigators 
foresee circumstances in 
the trial in which it may 
be practicable that some 
participants could enroll 
with prospective consent 
from the subject or LAR.   
In some trials the 
therapeutic window of 
the investigational 
therapy may require 
immediate administration 
(such as in victims of 
cardiac arrest or acute 
seizures) such that all 
participants are enrolled 
under EFIC, even if an LAR 
is present.  In other trials, 
such as the one described 
in this plan, there may be 
a narrow window in which 
consent from an LAR may 
be sought.  If the clinical 
situation may allow 
prospective consent from 
some participants, the 
plan should accommodate 
this option.   
When a trial will use both 
prospective consent and 
EFIC, the EFIC plan should 
provide clear and rational 
criteria for when 
prospective consent 
becomes impracticable 
and the EFIC enrollment is 





course of the study. If the LAR wants to continue the subject’s 
participation, the LAR will sign the informed consent form.   
An informed consent log is used to document the continuing efforts to 
locate an LAR, the notification of the LAR, the consent process, and 
the decision of the LAR.  This log will include the types of attempts 
made, the number and times of those attempts, and the outcome of 
each attempt.  If the subject regains decision-making capacity, the 
patient will be notified of the study and will be asked if he or she wants 
to continue the study.  If no LAR is found and the subject never 
regains decision-making capacity, the subject will remain enrolled 
under EFIC.  For subjects who expire prior to identification of an LAR, 
consent is not obtained. If an LAR is eventually located, they must be 
notified of the subject’s participation.  In the rare case where an LAR 
cannot be found and the subject remains incapable of consent at 6 
months, attempts to find an LAR will be discontinued, but 
documentation of the LAR search process until that time, and the 
subject’s decisional capacity, will be documented. 
Withdrawal from Participation 
Regardless of whether a subject was initially enrolled with informed 
consent or EFIC, an LAR may withdraw the subject from further 
participation at any time and for any reason.  If the subject regains 
consciousness and decision making capacity, subjects may also 
withdraw from further participation.  Whenever possible, the reason for 
wishing to withdraw should be determined.  Those wishing to just 
withdraw from the intervention (but not the study) should be aware 
that the intervention can be discontinued (i.e. request that the PbtO2 
probe be removed, or that ICU staff be unblinded to PbtO2 values) 
without withdrawing from the trial and further data collection.  
Discontinuation of the intervention itself does not constitute withdrawal 
from further participation in the study, so the study team needs to 
determine and accommodate what the participant or the LAR prefer.    
After withdrawing from either the intervention or any further 
participation in the study, the participant’s care should revert to usual 
care based upon patient characteristics, treating physician preference, 
and institutional practice.  Consistent with OHRP and FDA guidance, 
participant data collected prior to withdrawal from the study is 
maintained in the study database, but no additional participant data 
will be collected from the participant or their medical record following 
withdrawal from the study.   
 
  
Our experience in trials 
that will use both 
prospective consent and 
EFIC, is that sites should 
not be activated until they 
can enroll with EFIC.  The 
short-cut of starting with 
prospective consent may 
undermine the rationale 
and the subsequent 
implementation of EFIC. 
Ideally, the EFIC plan 
should include a 
procedure for tracking 
and documenting efforts 
made to seek an LAR.  
Depending on the trial, 
the search for an LAR may 
start before or after EFIC 
enrollment, but in any 
case there should be 
clearly documented 
efforts to find an LAR and 
notify them of the 
enrollment as early as 
possible.   
 
 
REGULATORY CRITERIA FOR USE OF EFIC 
The conditions under which EFIC is allowed are described in FDA 
regulations for trials conducted under an IND or IDE.  These same 
conditions are specifically referenced in the secretarial waiver and must also 
be met when an EFIC trial is performed under the secretarial waiver rather 
than an IND or IDE.  This trial fulfills these requirements for emergency 
research.  In the following section.  In this section, the components of the 
regulation are reproduced (in italics), along with an explanation of how this 
trial will comply with each requirement.  
TBI is life-threatening and available treatments are unsatisfactory or 
unproven. 
21 CFR 50.24(a)(1) The human subjects are in a life-threatening 
situation, available treatments are unproven or unsatisfactory, and the 
collection of valid scientific evidence, which may include evidence 
obtained through randomized placebo-controlled investigations, is 
necessary to determine the safety and effectiveness of particular 
interventions. 
TBI is a major cause of death and disability in modern industrialized 
societies, the scope of which is described in the study protocol.  Despite 
52,000 deaths from TBI annually in the US, and years of clinical 
investigation, there are still no proven specific treatments available.  
Although both ICP guided and PbtO2 guided goal-directed therapy are used 
in the care of patients with severe TBI, neither is proven to be effective. 
Numerous systematic reviews of various unsuccessful or persistently 
unproven interventions are available.  Further clinical trials are needed.  TBI 
has been recognized as a condition qualifying for EFIC in prior studies.  
Obtaining prospective informed consent is often not feasible.  
21 CFR 50.24(a)(2) Obtaining informed consent is not feasible because: 
(i) the subjects will not be able to give their informed consent as a result 
of their medical condition; (ii) the intervention under investigation must be 
administered before consent from the subjects' legally authorized 
representatives is feasible; and (iii) There is no reasonable way to 
identify prospectively the individuals likely to become eligible for 
participation in the clinical investigation. 
Eligible subjects with severe TBI are unconscious and unable to provide 
informed consent due to their medical condition. The critical care strategies 
being studied in this trial must be initiated rapidly after hospital arrival to 
have their intended effect. The hypothesized benefit of reducing tissue 
hypoxia in this trial relies upon early detection and correction.  Prior data 
demonstrate that brain tissue hypoxia is already present in many patients at 
the time that their monitoring was initiated.   
In a prior trial of 882 participants with moderate to severe TBI within 4 hours 
of injury, an LAR was not available to provide consent within 6 hours for 52% 
of participants.  When an LAR did not arrive within 6 hours, the time lag until 
an LAR did become available rapidly increased, with a median value of 
about 30 hours.  In this previous TBI trial, the consent for continued 
participation after EFIC enrollment and retention rates were very high.  
Without EFIC, the time and number of sites required to complete the trial 
would be impracticable.  Since TBI is accidental and unpredictable, there is 
no reasonable way to prospectively identify the individuals who will become 
eligible for participation in the research.  
The REGULATORY 
CRITERIA FOR USE OF EFIC 
section explains how the 
trial qualifies for EFIC by 
explicitly addressing all 
criteria of the regulations 
point-by-point.  
The italicized header 
summarizes the rationale 
for each regulatory 
requirement.   
This plan is formatted 
where the complete 
relevant regulatory 
requirements are 
provided verbatim in the 
indented italicized font. 
Investigator rationale for 
each criterion should be 
specific to the design of 
the proposed trial.  
Eligibility of the subjects 
in the trial should align 
with the populations 
described in these 
responses.   
To the extent possible and 
practical, these responses 
should be data driven.   
This example was for a 
trial that was determined 
not to be FDA regulated.  
Some of the responses 
used in this example may 
be insufficient to satisfy 
an FDA review. 
 
 
Participation holds prospect of direct benefit to subjects 
21 CFR 50.24(a)(3) Participation in the research holds out the prospect 
of direct benefit to the subjects because: (i) subjects are facing a life-
threatening situation that necessitates intervention; (ii) appropriate 
animal and other preclinical studies have been conducted, and the 
information derived from those studies and related evidence support the 
potential for the intervention to provide a direct benefit to the individual 
subjects; and (iii) risks associated with the investigation are reasonable 
in relation to what is known about the medical condition of the potential 
class of subjects, the risks and benefits of standard therapy, if any, and 
what is known about the risks and benefits of the proposed intervention 
or activity. 
Participation in sample TBI trial offers the prospect of direct benefit to 
subjects. Subjects may directly benefit from participation because TBI is a 
life-threatening condition and the PbtO2 goal directed interventions used in 
this study may be more effective than the ICP goal directed therapies alone.  
In particular, risks associated with the intervention, comparison of two goal-
oriented strategies of care, are reasonable in relation to what is known about 
severe TBI and its treatment.  The risks of intervention align with the range 
of risks of standard care as both strategies themselves are variations of 
standard care.  Some participants report comfort and appreciation from the 
attention and follow up from the study team that is inherent to their 
participation.  
The trial cannot be practicably carried out without exception from informed 
consent 
21 CFR 50.24(a)(4) The clinical investigation could not practicably be 
carried out without the waiver. 
This research could not be carried out without EFIC because treatment for 
TBI (including placement of probes and care driven by these measurements) 
needs to begin rapidly after hospital arrival.  Since TBI patients are unable to 
consent for themselves and there often is no LAR available within the 
therapeutic window of the proposed intervention, we expect that 
approximately half of the participants in this trial will be enrolled under EFIC.  
In TBI, time to treatment is critical.  Inability to obtain informed consent in the 
absence of EFIC can limit the ability to discover better treatments for this 
critical and life-threatening condition.  
Need for rapid treatment of TBI often precludes consent from an LAR 
21 CFR 50.24 (a)(5) The proposed investigational plan defines the length 
of the potential therapeutic window based on scientific evidence, and the 
investigator has committed to attempting to contact a legally authorized 
representative for each subject within that window of time and, if feasible, 
to asking the legally authorized representative contacted for consent 
within that window rather than proceeding without consent. The 
investigator will summarize efforts made to contact legally authorized 
representatives and make this information available to the IRB at the 
time of continuing review. 
The narrow therapeutic window described above, the inability of patients with 
TBI to communicate, and the lack of an LAR available to provide surrogate 
consent in more than half of potential subjects precludes the possibility of 
obtaining informed consent for many eligible patients in sample TBI trial.  
Attempts to contact LAR for notification and consent to continue participation 
will be tracked and summarized at continuing reviews.  
The prospect of direct 
benefit is required to 
offset risk inherent to EFIC 
enrollment.  It should not 
be interpreted as 
requiring a likelihood of 
direct benefit, which 
would be in tension with 
clinical equipoise.   
In trials in which an LAR 
may provide prospective 
consent for some 
participants, investigators 
should explain why it is 
not practicable to enroll 
just those subjects. There 
is no standard threshold, 
but in this case it would 
require twice as long or 
twice as many sites. 
These responses should 
provide specific 
information about the 
presumed therapeutic 
window of the 
investigational therapy.  It 
should be understood 
that therapeutic windows 
are rarely known with 
confidence and rarely 
have discrete boundaries.  
However, the response 
provided here should be 
based on a study 
definition for the 
therapeutic window that 
can be justified and that is 
internally consistent with 
assumptions and eligibility 
criteria used elsewhere in 
the study protocol.   
FDA often feels that 
investigators provide 
insufficient information to 





REGULATORY PROTECTIONS FOR IMPLEMENTING EFIC 
The regulations for EFIC research mandate additional requirements for the 
implementation of this kind of clinical trial.  Each of these additional 
protections and components of the regulation are reproduced (in italics) 
here, followed by an explanation of how the sample TBI trial will comply with 
the requirement.  Further details about implementation will follow in a 
subsequent section.     
Provision of an informed consent document 
21 CFR 50.24(a)(6) The IRB has reviewed and approved informed 
consent procedures and an informed consent document consistent with 
Sec. 50.25. These procedures and the informed consent document are 
to be used with subjects or their legally authorized representatives in 
situations where use of such procedures and documents is feasible. The 
IRB has reviewed and approved procedures and information to be used 
when providing an opportunity for a family member to object to a 
subject's participation in the clinical investigation consistent with 
paragraph (a)(7)(v) of this section. 
A written informed consent document for this study will be reviewed and 
approved by the study CIRB.  Subjects enrolled in this TBI trial, or their LAR, 
are approached for consent prior to enrollment or are informed of the 
subject’s inclusion in the clinical investigation at the earliest possible 
opportunity. The study team is immediately notified of the arrival of all 
potential subjects. An on-call study team member quickly responds to the 
hospital to enroll subjects or to complete the subject enrollment under EFIC.  
For the latter, the subject (or LAR or family) is approached, and a notification 
and/or an informed consent process initiated as soon as feasible. The study 
team notifies the subject or LAR/family about the subject’s enrollment, 
provides information about the study, the subject’s rights, and the 
responsibilities of the investigators.  The study team answers any questions 
about the study and further participation. A written informed consent 
document is used to reinforce the information provided in the consent 
discussion, and to document the decision to continue in the study or to not 
participate any further. A copy of this form is provided or offered to the LAR 
or subject and another copy is placed in the research record.  
Community Consultation 
21 CFR 50.24(a)(7) Additional protections of the rights and welfare of 
subjects will be provided, including, at least: (i) consultation (including, 
where appropriate, consultation carried out by the IRB) with 
representatives of the communities in which the clinical investigation will 
be conducted and from which the subjects will be drawn 
The community will be consulted prior to the initiation of research.  The 
community will be asked to give their opinions about the research and the 
need for EFIC in order to complete this trial.  A detailed menu of acceptable 
options for community consultation is included later in this plan.  The site will 
choose from this menu and perform sufficient consultations to ensure the 
CIRB that community consultation has been satisfactorily completed at each 
site.  Reporting of community consultation results will be standardized 
across the sample TBI trial sites. 
Public Disclosure 
21 CFR 50.24(a)(7) Additional protections of the rights and welfare of 
subjects will be provided, including, at least: ….(ii) Public disclosure to 




describes in general terms 
the plans and actions and 
actions that the 
investigators will pursue 
to be compliant with the 




If the study were FDA 
regulated, an informed 
consent document would 
also be included in the 







Plans and actions related 
to Community 
Consultation and Public 
Disclosure are described 
here in general terms.  
More detailed, granular 
descriptions of possible 
activities are provided 
later in the EFIC plan.  
 
 
the communities in which the clinical investigation will be conducted and 
from which the subjects will be drawn, prior to initiation of the clinical 
investigation, of plans for the investigation and its risks and expected 
benefits; (iii) Public disclosure of sufficient information following 
completion of the clinical investigation to apprise the community and 
researchers of the study, including the demographic characteristics of 
the research population, and its results 
Public disclosure is the primary element in making certain that this TBI trial is 
conducted in an entirely transparent manner. Methods of announcing 
information about the trial, and the development of advertising and other 
materials about the trial, will take place both locally and nationally.  Public 
disclosure will be initiated prior to approval of the trial, may continue during 
enrollment, and will conclude with dissemination of study results after the 
trial is completed.  A menu and discussion of many public disclosure 
methods and procedures is included later in this plan. The CIRB will approve 
the types and forms of public disclosure.  Reporting of public disclosure 
efforts will be standardized. Summaries of public disclosure will be reported 
to the CIRB, and made publically available. 
Data Monitoring Committee 
21 CFR 50.24(a)(7) Additional protections of the rights and welfare of 
subjects will be provided, including, at least: ….(iv) Establishment of an 
independent data monitoring committee to exercise oversight of the 
clinical investigation; 
A Data and Safety Monitoring Board (DSMB) is appointed to provide ongoing 
evaluation of safety data as well as the overall conduct of the trial, per 
institute guidelines.  The members will meet with the study team prior to 
study commencement to discuss the protocol as well as content and format 
of the DSMB reports.  The Data Coordinating Center will prepare requested 
reports at specified time intervals.  Data and safety monitoring will be 
performed consistent with the guidance provided by the NIH notices 98-084 
“Policy for data and safety monitoring” and OD-00-038 “Further guidance on 
data and safety monitoring for phase I and phase II trials”. 
Contacting Other Family 
21 CFR 50.24(a)(7) Additional protections of the rights and welfare of 
subjects will be provided, including, at least: …. (v) If obtaining informed 
consent is not feasible and a legally authorized representative is not 
reasonably available, the investigator has committed, if feasible, to 
attempting to contact within the therapeutic window the subject's family 
member who is not a legally authorized representative, and asking 
whether he or she objects to the subject's participation in the clinical 
investigation. The investigator will summarize efforts made to contact 
family members and make this information available to the IRB at the 
time of continuing review. 
Whenever possible, informed consent will be used in lieu of EFIC enrollment.  
EFIC enrollment will also not proceed if an LAR or any family or other 
surrogate present either at the bedside or remotely declines participation on 
behalf of the potential subject.  A provision of the protocol has been made to 
allow subjects who learn of the trial through public disclosure efforts or other 
means, and who, if treated in the hospital for TBI, would not want to 
participate, to communicate that decision to the ED without causing any 
delay in treatment.  As part of the primary assessment of any TBI patient, ED 
providers already check for medical alert jewelry to ascertain emergent 






A Data Monitoring 
Committee or DSMB is 
required for all EFIC trials. 
 
 
Unique to the EFIC 
regulations is a 
requirement to seek and 
honor a refusal to 
participate in the trial, 
when practicable, from 
any family member.  This 
is not restricted to an LAR.  
This objection may 
variously be anything 
from a fully informed 
refusal, to a general 
objection to research 
participation without 
specific knowledge of the 
particular trial.   The 
distinction between LAR 
and other family may be 
moot in most states since 
all family are usually in 
the LAR hierarchy and are 




declined,” or similar alternative designation, are listed on the medical alert 
tag, the patient will not be enrolled in the clinical investigation.  A 
hypoallergenic silicone bracelet may also be provided by the study team to 
members of the public if requested to indicate their wishes to decline study 
participation.  Use of this enrollment exclusion will be tracked and this 
information will be provided to the CIRB at the time of continuing review. 
Post Enrollment Notification and Consent to Continue 
21 CFR 50.24(b) The IRB is responsible for ensuring that procedures are 
in place to inform, at the earliest feasible opportunity, each subject, or if 
the subject remains incapacitated, a legally authorized representative of 
the subject, or if such a representative is not reasonably available, a 
family member, of the subject's inclusion in the clinical investigation, the 
details of the investigation and other information contained in the 
informed consent document. The IRB shall also ensure that there is a 
procedure to inform the subject, or if the subject remains incapacitated, a 
legally authorized representative of the subject, or if such a 
representative is not reasonably available, a family member, that he or 
she may discontinue the subject's participation at any time without 
penalty or loss of benefits to which the subject is otherwise entitled. If a 
legally authorized representative or family member is told about the 
clinical investigation and the subject's condition improves, the subject is 
also to be informed as soon as feasible. If a subject is entered into a 
clinical investigation with waived consent and the subject dies before a 
legally authorized representative or family member can be contacted, 
information about the clinical investigation is to be provided to the 
subject's legally authorized representative or family member, if feasible. 
Subjects enrolled in this TBI trial, or their LAR, are informed of the subject’s 
inclusion in the clinical investigation at the earliest possible opportunity as 
detailed elsewhere.  It is anticipated that the notification of subjects, or their 
families or LAR, will most commonly take place in the ED within hours of 
subject enrollment.  Attempts to notify the subject or an LAR are repeated 
until successful.  All notification attempts for a subject are logged in the 
subjects’ case report form. Summaries of attempts are available for reporting 
to the CIRB. 
Record Keeping 
21 CFR 50.24(c) Like other IRB records, records of the determinations 
above must be kept for a minimum of three years after the completion of 
the clinical investigation. Again, like other IRB records, these are subject 
to inspection and copying by FDA. 
Records documenting the enrollment of participants using EFIC, procedures 
for notification of enrollment, and informed consent forms will be kept for a 
minimum of three years after completion of the clinical investigation. 
IND/IDE Requirement 
21 CFR 50.24(d) Protocols involving an exception to the informed 
consent requirement under this section must be performed under a 
separate investigational new drug application (IND) or investigational 
device exemption (IDE) that clearly identifies such protocols as protocols 
that may include subjects who are unable to consent. The submission of 
those protocols in a separate IND/IDE is required even if an IND for the 
same drug product or an IDE for the same device already exists. 
Applications for investigations under this section may not be submitted 




If a clinical trial is subject 
to FDA regulations and 
will be conducted 
pursuant to 21CFR50.24, 
then an IND or IDE specific 
to the EFIC trial is always 
required.  See the FDA 
guidance for differences 
between drugs and 
devices.  FDA guidance 
recommends contacting 
FDA for clarification 
regarding requirements 
for IDE submission for 
EFIC trials involving any 
medical device.   
EFIC trials that are not 
FDA regulated, but are 
regulated under 45CFR46 
are still required under 
the HHS Secretarial 
Waiver at FR Doc. 96–
24968 to meet the 
conditions described at 
21CFR50.24.  However, 
trials that are not FDA 
regulated do not have an 
IND or IDE. 
EFIC trials conducted 
under the HHS Secretarial 
Waiver at FR Doc. 96–
24968 have additional 
restrictions excluding  





The sponsor has notified FDA about this trial, provided the study protocol, 
including intent to enroll with EFIC, and has answered all questions from the 
Agency. After discussion, the Agency has determined that an IDE is not 
required for this trial.  The Agency has pointed out that this finding is 
consistent with their latest guidance on EFIC specifically for device trials.   
Communication of IRB Determination 
21 CFR 50.24(e) If an IRB determines that it cannot approve a clinical 
investigation because the investigation does not meet the criteria in the 
exception provided under paragraph (a) of this section or because of 
other relevant ethical concerns, the IRB must document its findings and 
provide these findings promptly in writing to the clinical investigator and 
to the sponsor of the clinical investigation. The sponsor of the clinical 
investigation must promptly disclose this information to FDA and to the 
sponsor's clinical investigators who are participating or are asked to 
participate in this or a substantially equivalent clinical investigation of the 
sponsor, and to other IRBs that have been, or are, asked to review this 
or a substantially equivalent investigation by that sponsor. 
Pursuant to the NIH single IRB policy for multicenter clinical trials, sample 
TBI trial will be reviewed and approved by a single CIRB.  If the CIRB does 
not approve the trial, no subjects will be enrolled at any site, and all 
stakeholders will be informed.  Because of a single IRB of record, there will 
be no opportunity for discordant IRB findings, and no other reporting of 
disapprovals.   
 
   
An IND or IDE will almost 
always be required if 
there is any interpretation 
that an investigational 
drug or device is involved.  
FDA guidance clearly 
indicates that any EFIC 
study involving an FDA 
regulated product be 
evaluated by FDA for a 
determination as to 
whether an IDE or IND is 
needed. 
 
The revised Common Rule 




COMMUNITY CONSULTATION PRINCIPLES 
Implementation of community consultation in this trial is based on the 
applicable regulatory language, applicable FDA guidance documents 
(from March 2011, updated April 2013), and the investigators own 
empirical ethics research and experience in developing best network 
practices.   
 
Goals 
The regulatory intent and specific goals of community consultation are 
not explicit in the regulations, and have been the subject of academic 
disagreement.  As described in the FDA guidance, the goals of 
community consultation include: 
● To show respect for persons by informing the community 
about the study in advance; 
● To inform community members about the trial in advance and 
provide a means for affected communities to provide 
meaningful input to the IRB before its decision to approve, 
require modifications to, or disapprove the study; 
● To show respect for the community by allowing 
representatives of the community to identify 
potential community-level concerns and effects of the research; 
and   
● To show respect for subjects’ autonomy. Respect may be 
shown by including in community consultation activities 
individuals who may have, or be at risk for, the condition 
under study (and thereby obtain input from a group that is 
expected to be similar to the eventual study subjects).  
 
This EFIC plan incorporates and interprets these goals into the 
following specific actionable elements.   
To show respect for persons, we require CC events that include 
going out into the community to talk to people where they already 
gather, rather than simply asking them to come to us at events that we 
originate.  Showing respect also involves CC events that specifically 
engage the investigators responsible for the research with the 
members of the community, rather than only allowing consultations 
that can be outsourced or delegated.   
To create effective opportunities for the affected communities to 




describe the underlying 
goals and principles upon 
which the proposed plans 
for community 
consultation are based. 
Unlike the prior section, 
these principles are not 
defined in regulation or 
guidance.  The principles 
laid out here, however, 
are general and may be 
applicable across EFIC 
trials.  The text on this 
page, therefore, could be 
reused verbatim for 
future trials’ EFIC plans, if 
compatible with the 
investigators’ principles 
and interpretations.   
 
 
formats that ensure that study teams listen as much as they talk.  
Simply giving a presentation about the trial and then asking if there 
are any questions is not effective CC.  Deliberately brief descriptions 
of the trial, preferably with few or no slides, are followed by probing 
the community members for what additional information is important to 
them, and by soliciting the values and experiences of the community 
members that are most relevant to the research and to TBI.  
Community members are experts about themselves.  How their own 
narratives intersect with the proposed research and the way in which it 
will be carried out (under EFIC) is the most useful input the community 
can provide to the IRB. 
To show respect for the community, CC activities explicitly reach out 
both to individuals in the community without specific roles, and to 
representatives of the community.  Representative of the 
community may be religious leaders, community organizers, patient or 
disease advocates, local political leaders, or others best equipped to 
identify group-level concerns.   
Demonstrating respect for the autonomy of a group of individuals 
who may have, or be at risk for, the condition under study is 
particularly challenging in TBI research because traumatic injuries can 
happen to anyone.  We meet this goal by asking sites to describe the 
breadth and depth of the communities they serve, and then asking 
that they complete CC activities that reflect a sufficient portion of that 
spectrum.  In past TBI trials we have specifically sought out 
communities that are high risk of TBI, but that may be hard to engage 
in CC, such as Motorcycle or ATV Clubs and young adult males 
playing basketball or football.   Sites have historically accessed TBI 
support groups to speak to TBI victims and their caretakers as well.  
These groups are keenly aware of possible treatments and the cost a 
traumatic TBI can have on one's quality of life.     
It is also important to explicitly reinforce the FDA guidance by stating 
the goal of CC is not intended to represent community consent.  
Consent to participate in research is meaningful only as an individual 
decision; community support of the research does not reflect consent 
for all members of the entire community.    Community consultation is 
therefore not intended to be a form of unbiased voting, deliberative 
democracy, or other purely quantitative activity, but rather an 
opportunity for open discussion and commentary.  The IRB makes the 
final determination on study approval based on information obtained 










Here, with regard to the 
disease-specific or risk-
specific community, there 
may need to be some 
trial-specific language 
added as shown here. 
 
 
Definition of Community 
For the purposes of EFIC, the definition of community includes “the 
community in which research will take place” and the “community from 
which subjects will be drawn.”  In other words, the community includes 
the geographical area from which patients will be drawn and the group 
of patients with, or at risk for, the disease of interest.  Communities 
have many subgroups that can be defined by innumerable 
characteristics such as race, ethnicity, religion, age, gender, wealth, 
education, employment, neighborhood and other factors.  Community 
consultation should consider the heterogeneity of the community and 
seek diverse input.  It is understood, however, that it is impracticable 
to reach every possible subgroup, but each site will complete activities 
that reflect a sufficient portion of the spectrum of their relevant 
communities.    
Content 
The content of community consultation will inform the community 
participants that informed consent will be obtained for any research 
subjects prior to enrollment whenever possible, and will not be 
obtained when no LAR is available.  Informational materials developed 
for sample TBI trial CC activities are included in the appendix of this 
plan and are subject to IRB approval.  Additional materials developed 
later will be submitted to the IRB for approval before being used in any 
CC/PD activities.  Specifically, the content of all CC activities will: 
● Tell the community about the most relevant aspects of the trial 
including its potential risks and potential benefits, and the 
therapeutic window (based on timing of probe placement, but 
generally within about 2-10 hours of injury). 
● Hear the perspective of the community on the proposed 
research, elicit values and experiences 
● Explain how individuals wishing to be excluded may indicate 
this preference 
Types of Events 
Based on our interpretation of the regulations and their proposed 
ethical basis, we have prepared a menu of the types of events and 
activities that sample TBI trial sites may use to meet their 
requirements for CC.  Sites will prepare a site plan that lists all the 
events and activities that they will use to engage the community.  
Each site plan will:  
This section of the plan 
emphasizes the 
consideration of diversity 
within communities.  
Investigators may ensure 
representativeness 
through a combination of 
activities, some of which 
are aimed at general 
community with diverse 
participants, and other 
diverse activities that 
focus specifically on key 
subgroups.  Key 
subgroups that may 
benefit in particular from 
focused efforts at 
inclusion may be those 
that are historically 
underserved, neglected, 
or vulnerable.  IRBs may 
differ in expectations, but 
our experience is that IRBs 
appreciate some focused 
efforts with regionally 
prevalent racial and 
ethnic minorities, the 
elderly, and perhaps 
applicable poor or rural 
communities.   




abuses of research 
without consent in African 
American and other 
vulnerable communities in 
the context of EFIC when 




● Provide opportunities for broad community discussion 
● Ensure that representatives from relevant communities 
participate in the consultation process 
● Include more than one type of event or activity to provide for 
effective community consultation 
● Consider multiple factors including, but not limited to, the size 
of the communities, the languages spoken within those 
communities, the heterogeneity of the population 
 
  
FDA guidance on the 
content of community 
consultation events 
includes 24 bulleted 
items.  Respectful and 
effective consultations, 
however, may involve 
allowing community 
members and groups to 
participate in driving the 
agenda and content. 
 
 
COMMUNITY CONSULTATION MENU 
 
A ( Interactive - Direct ) B ( Asynchronous - Delegated) 
A presentation and discussion 
by an investigator visiting a 
meeting of an existing group 
(visits to existing meetings)  
Telephone survey (random digit 
dialing) 
Focus group (moderated small 
group session) 
Web-based survey 
In-person individual interviews or 
meetings  
Social media messaging 
A booth or table at community 
events involving  interactive 
discussions (not just surveys) 
In person solicited survey e.g., 
waiting room survey, booth 
survey without other interaction 
Meetings convened by the 
investigators inviting the 




Required mix is at least 6 total CC events or activities.  Among these 6 
events or activities, at least 2 events or activities must be of a type in 
column A, and at least 1 event or activity must be of a type in column 
B.  The 2 events of a type in column A may be of the same type, for 
example, they could both be focus groups or visits to existing groups.  
Events should include participants representing a sufficient breadth of 
the diversity of both the geographic community primarily served by the 
enrolling sites’ institution, and the community either at-risk for, or 
familiar with, TBI.  There is no expectation that all of the subgroups of 
either community can be engaged.  However, 6 events is just a 
minimum, and it is expected that enough events will be completed to 
reach a meaningfully broad and diverse cross section of community.  
Quality is just as important as quantity of activities. 
Visits to existing meetings or existing groups 
In this method of community consultation, members of the study team, 
sometimes accompanied by representatives of their participating 
institutional research leadership, ask to present the study and lead a 
discussion about the study at a regularly scheduled meeting of a 
relevant community group.  Sometimes, the existing group may hold a 
special meeting for this purpose, but the study team still goes to the 
group (rather than asking members of the group to come to the study 
team).   
The COMMUNITY 
CONSULTATION MENU 
section describes specific 
menus and descriptions of 
the types, numbers, and 
mix of events in which 
sites are required to 
engage. 
The intention of the 
community consultation 
menu of activities is to 
provide multi-dimensional 
community engagement 
while also allowing 
sufficient flexibility at sites 
to ensure that sites can 
adapt the plan to the 
most effective outreach 




FDA stresses that there is 
no magic number of 
events required, but 
rather is whatever is 
needed to meet the goals 
of community 
consultation.  This plan 
agrees, but surmises that 
these goals can never be 
accomplished in fewer 
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Existing groups that might be consulted using this method may 
include, but are not limited to: disease-related support or interest 
groups, civic groups, neighborhood groups, service organizations, 
athletic groups (inclusive of athletes, coaches, and trainers at any 
level of competition from high school to professional), parent-teacher 
associations, faith-based organizations, political or governmental 
bodies, business groups, social clubs, retiree groups, and college 
fraternities or others.  Examples of disease-related support groups 
include TBI support networks of parents of children and young adults 
with TBI.  Examples of governmental bodies include law enforcement 
and fire department groups, city councils, and community boards.  
This approach may also include study team visits to senior centers or 
rehabilitation facilities.  Participation in an existing meeting shows 
respect for community by bringing the information to the community, 
reduces inconvenience to the community and exposes the study to a 
diverse audience.  Community members may be more comfortable 
expressing their opinions in a known setting.  Investigators may have 
to travel, attend multiple meetings and conform to the community 
group’s schedule.  Using this method can encourage more 
involvement by co-investigators and other members of the study team, 
which can be advantageous. 
Prior to and during the visit, the study team must clearly communicate 
that being allowed to attend the meeting does not imply any implicit 
approval or endorsement by the group being visited. 
Best Practices: 
● An investigator should be present to take and answer questions 
from the community. 
● Presentation should be brief (i.e., 10 to 15 minutes). 
● If a presentation is longer than 15 minutes, it should be 
interactive throughout the presentation. 
● The presenter should be knowledgeable about the study and 
comfortable with the group.  
● Allow ample time for community discussion (at least 15-30 
minutes). 
● Often best to ask for 30 minutes on an existing meeting agenda 
to allow 10 minutes to present, 15 minutes for discussion, and 5 
minutes to hand-out and get back evaluation surveys.  
Insufficient time for solicitation of feedback greatly reduces the 
utility of this method. 
● Probe for discussion using open-end questions.  Ask 
participants about their experiences and what they care about. 
● Ensure that the discussion includes feedback from the 
participants on EFIC. 
Recent community 
consultation experiences 
have changed since the 
onset of social distancing.  
Restrictions on gathering 
create challenges for 
engagement.  Attending 
community events with 
staffed boots are no 
longer possible.  Visits to 
existing meetings are still 
possible, but only when 
such meetings have been 
replaced with virtual 
encounters.  Focus groups 
and individual interviews 
and meetings, and 
telephone, web-based, 
and social-media-based 
activities have been less 
affected.  Alas, light 
refreshments are no 
longer provided.  This 
template EFIC plan 






● Light refreshments may be sponsored; direct monetary 
incentives are uncommon. 
● An anonymous survey for group participants to indicate their 
thoughts, feelings, and opinions about the EFIC regulations and 
the study is typically collected at the end of the event.  The 
survey template is available on the sample TBI trial website in 
the toolbox under EFIC. 
 
Focus groups 
In this approach, a trained facilitator interviews and moderates a 
discussion in several small groups (generally about 8 to 12 
participants).  This method can be conducted with or without an 
investigator present, but the former is favored.  Unlike focus groups 
designed for other research purposes, these focus groups are 
performed as community consultations.  They are an opportunity for 
investigators to directly listen to community members, and to show 
their respect by listening humbly.  An investigator may often start the 
session by briefly presenting information about the trial or may elect to 
allow the facilitator to proceed, and listen and be available to clarify 
issues and answer questions.  The facilitator runs the discussion using 
an explicit guide prepared by or reviewed beforehand by the 
investigative team. The facilitator elicits the group’s views, questions, 
concerns and comments about the study.  The interaction is generally 
audio-taped (and possibly videotaped) for review by the investigative 
team and the facilitator to allow subsequent analysis and reporting of 
the session.  Focus groups could solicit feedback from any relevant 
focus of the community, including: the general public, individuals 
affiliated with particular organizations or subgroups, or specific patient 
populations.   
Recruitment methods for focus group participants will depend on the 
targeted population.  Participants may be recruited by mail or 
telephone, at random from volunteer banks or public data sets or from 
special populations (such as patients with prior brain injury or their 
families, advocacy group representatives or other vested interest 
groups).   
Compared to other methods of community consultation, focus groups 
may allow for more in-depth discussion of the study because of their 
small size.  They also allow for interaction not only between the 
facilitator and participant but between participants.  For these reasons, 





such as focus groups, may 
require more resources 
than other activities.  This 
example EFIC plan 
assumes sites can be 
sufficiently funded to 
perform the activities 
suggested by the plan.  
Individual trials may have 
to adjust their EFIC plans 
and expectations to 
accommodate the 
available budgets.  
However, ethical and 
regulatory obligations are 
not different for trials 
with lower budgets. 
 
 
by investigators and IRB members to be a high-quality source of 
information.   
Best Practices: 
● The meeting should be at an accessible location and time for 
the population included. 
● The session should generally be run by a trained facilitator; 
sometimes it is helpful if it is someone who is also 
demographically concordant with the focus group participants 
(experience, race, ethnicity, or gender). 
● Sessions should be small, generally including 8 -12 
participants. 
● Focus groups generally run 1 to 2 hours in length. 
● Refreshments should be provided. 
● Participants are generally paid for participation in focus group 
sessions in an amount and form appropriate to the participant 
population. 
● An anonymous written survey for group participants to indicate 
their thoughts, feelings, and opinions about the study and the 
focus group session should be conducted at the end of the 
event.  
Convened (invited) meeting 
Sometimes called a “Town Hall Meeting”, this type of CC uses the 
same structure and best practices as visits to regularly scheduled 
meeting, but invites a target audience to a meeting convened by the 
study team.  The potential advantage of this method is that multiple 
groups of attendees can be invited to the meeting, and have a chance 
to interact with each other and the investigator.  Because the meetings 
are typically open to the public, there is the potential to involve 
everyone.  The disadvantage with this method is that organizing such 
a meeting and attaining adequate attendance can be burdensome and 
difficult.  To be successful, however, an intensive effort to diligently 
invite several potential attendees and secure their commitment to 
participate is needed.  Merely advertising a public meeting and seeing 
who shows up leads to events with very few community members.  
Such low attendance events have been commonly held in prior EFIC 
trials, but are not acceptable for sample TBI trial.  The use of invited 
meetings, therefore, is discouraged unless the site has a track record 






Community events - interactive or survey 
In this type of event, the study team and investigator typically set up a 
booth or table at an existing community event and interact with 
individuals one at a time as they browse or stop by the booth.  Events 
of this kind have occurred at State Fairs, Fire and Emergency 
Services Open Houses, Farmers Markets, Art Festivals, Music 
Concerts, Health Fairs, Ice Cream Socials, Disease-related 
Fundraising Events, Tailgates and other Sporting Events.  This kind of 
event often allows exposure to a large number of community 
members.  Depending on the kind of event it may allow investigators 
to reach a focused or very diverse group and a large number of 
participants.  Because conversations are typically one on one, this 
method often allows more intimate and revealing opportunities for the 
investigator and members of the public to interact.  Disadvantages of 
this approach is that most of the contacts are very brief, usually 
limiting the opportunity to exchange information.  Also, the time 
commitment from the study team to staff the booth for the duration of 
the event may be significant, making this potentially inefficient.  This 
type of event can be conducted in a way that is more interactive (a 
column A event), in which an investigator or other study team member 
primarily engages participants in conversations, often concluding with 
having the participant fill out a survey either through an interview or by 
completing a written tool.  The event can also be conducted in a way 
that is primarily driven by just giving out written information about the 
study and asking participants to fill out a written survey (a column B 
event).  In this case, the booth can be staffed without an investigator 
present, which can be more efficient for the study team.   
Best Practices: 
● Booths should have good signage that attracts passers-by.   
● Have small treats or “swag” to attract participants and thank 
them for taking time to talk to you. 
● Have enough staff at the booth to engage with anyone who 
wants to talk. 
● Have enough clipboards and pens to make certain no one has 
to wait to complete written feedback. 
● It is often effective to make this kind of event a fun social team-
building exercise for the study team.   
 
Telephone (random digit dialing) survey  
Large telephone surveys can provide the most statistically 




the study and EFIC.  This approach also has the potential to access 
the views of members of the community that are unlikely to attend 
other types of community consultation activities.  This kind of survey is 
often outsourced to a vendor.  Vendors are often costly, but because 
they can deliver rapid, predictable data, and consume relatively little 
study team time, this approach can still be efficient.  Interviewers 
should be trained by the study team about sample TBI trial.  
Telephone surveyors are trained to read information verbatim 
provided to them by the study team about the study and EFIC.  They 
then ask close-ended questions and solicit open-ended comments 
and questions.  This information is then summarized and reported 
back to the investigators and the CIRB.  It is important that the survey 
and accompanying guide used by the interviewers should be carefully 
written and tested by the study team.  Vendors can potentially perform 
large online surveys that are akin to these large random digit dialing 
surveys. 
There are several limitations to this method.  Telephone surveys can 
be intrusive and unwelcomed.  Also, because they are delegated 
rather than conducted directly by the investigators, they do not allow 
investigators to demonstrate the same level of interpersonal respect 
for persons or communities as other methods.  Questions are typically 
narrow and closed ended in this approach.  Professional surveyors 
are also not generally equipped to answer clarifying questions about 
the trial or EFIC.  To achieve a reasonable sample size, telephone 
surveys have to be short.  The presentation of EFIC and BOOST3 is 
therefore necessarily very limited, so responses may not be as well 
informed or may be less reflective than responses solicited in more 
interactive methods.  The extent to which this method produces 
systematically different responses is unknown.   
 
Simple solicited surveys like those performed online, in waiting rooms, 
or at booths 
Simple individual surveys, whether performed on-line or in person, can 
also be used to solicit community questions and views.  This method 
can be used to reach large numbers and a wide variety of 
respondents.  Online surveys can be linked to social media platforms 
or can be easily solicited by email.  Respondents can also be recruited 
to complete surveys distributed in-person in relevant clinical settings 
like emergency department or clinic waiting rooms.  These simple 
survey methods may not be as statistically representative as 
telephone surveys, but can be potentially provide more background 




also allow respondents to see visual aids and diagrams not possible 
with telephone surveys.  Waiting room surveys may allow focus on 
populations with particular health care or TBI experience.  Online and 
waiting room surveys otherwise have the same limitations as 
telephone surveys.  Careful writing and testing of surveys remains 
critically important. If surveys are distributed in person, surveyors 
need to be well trained in the study protocol and in the EFIC 
regulations. 
Best Practices: 
Whenever possible, these surveys should be conducted by members 
of the study team, and or delegated surveyors with medical knowledge 
and training in the protocol and EFIC. Medical students and residents 
can sometimes be recruited as surrogates for the investigative team. 
 
Other social media 
Social media offers a low cost, potentially far reaching, and potentially 
interactive method to exchange information with members of a 
community.  Recent data suggest that the penetrance of social media 
is very high with 80% of adults in the US accessing Facebook, 
Youtube, Instagram, Pinterest, Snapchat, LInkedin, Twitter, or 
WhatsApp daily (while only 29% read print newspapers daily).  Social 
media may also allow messages to be directed to selected subgroups 
and demographics.  However, investigators should still be aware that 
despite the high prevalence of social media overall, that use is still 
somewhat weighted toward younger adults, those living in suburbs, 
those with higher incomes, and those with more education.  Also 
different platforms are favored by different demographics. Social 
media is a medium that blurs the line between one way 
communication (as used in public disclosure) and dialog (as used in 
community consultation).  The former type of use is probably more 
common, but truly interactive social media communications are also 
possible.  If chosen as a CC activity, the content of the presentation, 
the methods to allow interaction, and gaps in the available population 
should be clearly described. 
REPORTING COMMUNITY CONSULTATION RESULTS 
All community consultation activities must be reported to the CCC via 
the Community Consultation (CC) Form in CTMS.  Here, study site 
personnel will data enter the aggregate data of their community 
consultation activities, by event.  Data captured includes:  information 










Prevailing culture, access 
to various platforms, and 
near-ubiquity of 
technology is rapidly 
changing the potential for 
social media in 
community engagement.  
Constant innovation and 
learning will likely allow 
this section to expand in 
the near future to include 
more suggestions and 
best practices that are still 











section describes how the 
results should be reported 
to the CIRB. 
Reporting CC to the public 
FDA docket is not 
required under 21 CFR 
50.24 as it is for PD, but 
including these CC reports 
with the PD submissions is 




comments, and responses to closed- and open-ended survey questions.  
A complete list of CC Form data fields is available on the sample TBI trial 
website in the toolbox under CTMS.  The results will be further collated to 




PUBLIC DISCLOSURE PRINCIPLES 
Public disclosure is defined in guidance as the “dissemination of 
information about the research sufficient to allow a reasonable 
assumption that communities are aware of the plans for the 
investigation, its risks and expected benefits and the fact that the 
study will be conducted”. It also includes “dissemination of information 
after the investigation is completed so that communities and scientific 
researchers are aware of the study’s results”.   
Goals 
The regulatory intent and specific goals of public disclosure are not 
explicit in the regulations, and have been the subject of academic 
disagreement.  This plan is based on the presumption that the primary 
goal of public disclosure is transparency.   
Transparency is achieved when information about the study is broadly 
and publicly disseminated through multiple channels.  We note that 
transparency has a protective effect because investigators will not 
propose anything that they would not be willing to announce and 
defend openly.  
Adequacy of public disclosure and transparency is best measured by 
the size of the potential audience of the disclosure, rather than by 
knowledge or recollection of the audience.  Awareness is a poor 
metric because the more benign and acceptable a clinical trial is, the 
less likely the content of the public disclosure will be internalized and 
recalled.   
Content 
The content of public disclosure materials will vary with the media 
used.  Advertisements (whether signs, print media, broadcast, or 
electronic) may have limited space.  These disclosures may convey 
short messages and how the audience can obtain more detail.  Follow 
up examples may include ways to talk to the study team, or a link to 
the study website.  Short messages should at a minimum emphasize: 
● That a research study of patients with traumatic brain injury is 
being conducted locally. 
● That the study will enroll patients with injuries that prevent them 
from participating in informed consent. 
● Who to contact or where to find additional information. 
  
Similar to the prior section 
on Community 
Consultation principles 
and practices, the PUBLIC 
DISCLOSURE PRINCIPLES 
section describe the 
underlying goals and 
principles upon which the 
proposed plans for public 
disclosure are based. 
Again, these principles are 
not defined in regulation 
or guidance.  The 
principles laid out here 
are general and may be 
applicable across EFIC 
trials.  The text on this 
page, therefore, could be 
re-used verbatim for 
future trials’ EFIC plans, if 
compatible with the 
investigators’ principles 




FDA guidance on the 
content of public 
disclosure includes 13 
bulleted items.  An 
example of one of these 
bullets is the study 
informed consent 
document.  While all the 
listed content can be 
public, clearly not every 
piece of PD material can 
contain every element of 
content.  A bus ad or 20 
second public service 
announcement is limited.  
However, all items can say 
where to learn more.  
 
 
Other forms of disclosure, such as press releases, websites, or 
brochures for example, allow for greater detail and should, depending 
on available space, also include: 
● Information about TBI and how it is treated 
● The purpose of the research 
● Who will be included in the study 
● A description of the two treatment strategies being compared 
● A balanced description of the potential clinical and research 
risks and benefits 
● Synopsis of the research protocol and study design 
● Participating sites/institutions 
● Description of the attempts to contact a LAR 
● Information about opting out of the study 
After the clinical trial is completed, further public disclosure should 
include: 
● The findings of the trial 
● Impact of what was learned on patient care 
● Where to find resources for further information 













The primary manuscript, 
especially in a high profile 
journal is an important 
form of post-trial public 
disclosure.  The 
demographics of those 
enrolled should be 
included in the paper, and 
are included with public 
disclosure posted to the 
FDA docket.  
 
 
PUBLIC DISCLOSURE MENU - PRE-TRIAL 
 
A (networking) B (paid advertising) C (conventional 
outlets) 































(banner, block, or 












Many different channels of public disclosure should be used.  This will 
increase the depth and breadth of market penetration.  The required 
mix is at least 6 total PD activities including at least 2 of a type in 
column A, and at least 1 of a type in column B or column C.  
Distribution of activities should be cognizant of the anticipated 
audiences, and should include audiences representing a sufficient 
breadth of the diversity of both the geographic community primarily 
served by the enrollment site, and the community either at-risk for, or 
familiar with, TBI.  There is no expectation that all potential audiences 
will be reached.  It is expected that PD efforts will represent a good 
faith effort to provide transparency across the relevant communities. 
Networking 
Electronic platforms can provide a passive or interactive approach to 
disseminating information that has benefits and challenges.  
Measurement of the audience reached by these methods may be 
elusive.  Access may be limited to those segments of the population 
The PUBLIC DISCLOSURE 
MENU section describes 
specific menus and 
descriptions of the types, 
numbers, and mix of 
activities in which sites 
are required to engage. 
The intention of the public 
disclosure menu of 
activities is to provide 
multi-dimensional 
community notification 
and transparency while 
also allowing sufficient 
flexibility at sites to 
ensure that sites can 
adapt the plan to the 
most effective outreach 







As noted previously, FDA 
stresses that there is no 
magic number of events 
required, but rather is 
whatever is needed to 
meet the goals of public 




with regular computer access, although internet access through cell 
phones is rapidly becoming common in all parts of society.  Despite 
these minor concerns, electronic social media and other e-platforms 
are inexpensive to develop, are wide-reaching and can be relatively 
democratic, and can even permit continuous and anonymous input 
from the public.  Hospitals and community based organizations often 
host and curate websites, social media accounts (Facebook, Twitter, 
etc) and listservs, that can be efficiently leveraged to disseminate a 
message broadly.  
 
Paid advertising 
Purchased advertising in broadcast and print media ensures 
dissemination of accurate materials to a wide audience. 
Advertisement of the study may occur on a major news radio station 
serving the area surrounding the study hospitals.  A 30 to 60 second 
sound bite should include a general description of the study, the 
website address, and contact information where more information can 
be provided if desired.  Printed materials, including advertisements for 
publication in newspapers and magazines, brochures, and flyer, are 
available electronically on the sample TBI website.  Advertisements 
should be placed in both English language and foreign language 
newspapers as appropriate to the local community.  Printed 
advertisements should provide a general description of the study, the 
national and/or local website address, as well as site contact 
information. 
Conventional informational outlets 
Press releases leading to newspaper and periodical articles are an 
effective form of public dissemination.  Investigator appearances on 
local news, radio or television call-in talk shows can accomplish both 
public disclosure and community consultation.  In addition to 
traditional news outlets, it is often possible to obtain coverage in local 
health focused newsletters, in direct mail advertisements and 
educational materials sent out by health care organizations and in 
newsletters of TBI advocacy and support groups.  A video on 
emergency medicine trials and EFIC research in general will be 
available for use in public service announcements and for 
dissemination to media outlets.  Local community access cable 
stations may be accessible to investigators.  Cable access channels 
may offer appearances on shows presenting issues of local interest or 




Brochures and flyers may be disseminated in locations including: 
● Medical sites (e.g., emergency department waiting rooms, 
medical clinics, dentist offices, etc.) 
● Health fairs (community, employer, school, etc.) 
● Support groups and other existing community groups 
● Schools, universities,  
● Churches and other religious affiliates 
● Grocery & laundry-mat bulletin boards 
● Through large employers (i.e., hospitals, universities, etc.) 
Local flyers and brochures distributed should reference the trial 
website as an additional resource for patients, families, and healthcare 
providers to get information as well as ask questions about the trial.   
 
PUBLIC DISCLOSURE ACTIVITIES - POST-TRIAL  
Post-trial public disclosure activities may include any of the methods 
used pre-trial, especially press releases because results of trials can 
be especially newsworthy.  Post-trial public disclosure also includes a 
number of more specific additional methods.  Post-trial disclosure 
includes publication of the trial results in a major scientific journal and 
presentation of the results at scientific meetings.  Through these 
publications and presentations, it usually possible to leverage the 
existing public relations machinery of the journals and the meeting to 
amplify the message through broader media outlets as well.  Another 
specific post-trial public disclosure method is return-of-results to the 
study participants and their families.    
 
 
REPORTING PUBLIC DISCLOSURE ACTIVITIES 
All public disclosure activities must be reported to the CCC via the 
sample TBI trial Public Disclosure (PD) Form in CTMS.  Study site 
personnel will data enter data on each activity including:  name and 
type of activity, size of anticipated audience, and characteristics of the 
intended audience, and timing and duration when relevant.  A 
complete list of PD Form data fields is available on the sample TBI 
trial website in the toolbox under CTMS.  Activity data will be further 






































The REPORTING PUBLIC 
DISCLOSURE RESULTS 
section describes how the 
results should be reported 
to the CIRB.   
Reporting PD to the public 
FDA docket is also an 
explicit obligation for 
trials conducted under 21 
CFR 50.24.  These trial 






CONTACTING A LEGALLY AUTHORIZED REPRESENTATIVE (LAR) 
The definition and hierarchy of LAR is determined by local state 
regulations.  
When more than one LAR are present, the LAR highest in the local 
hierarchy should give consent. However, unless otherwise stated in 
local or state regulations, any LAR may consent if others are not 
promptly available.  
EFIC does not obviate the need to seek an LAR to provide consent 
prior to enrollment if possible, and to seek patient or LAR consent to 
continue participation after EFIC enrollment. Potential subjects are 
also not enrolled under EFIC if any family contacted prior to 
enrollment objects to enrollment, even if they are not an LAR or are 
only available by telephone.  Subjects enrolled in sample TBI trial, or 
their LAR or family, are informed of the subject’s inclusion in the 
clinical investigation at the earliest feasible opportunity. The study 
team is immediately notified of the arrival of potentially eligible patients 
in the emergency department (ED). An on call study team member 
quickly responds to the ED to determine eligibility, seek an LAR for 
consent, and enroll the subject if consent is obtained or enroll under 
EFIC when appropriate.  The subject (or LAR or family) is 
approached, and an informed consent process initiated as soon as 
possible. 
LAR identification and tracking will typically be a shared responsibility 
between the onsite social workers (or equivalent) and the study team. 
Each site PI and team will meet with their social workers (or 
equivalent) before the trial initiation to inform them of the trial protocol 
and need for intensive LAR search. The site team should review the 
local protocol for an LAR search and assure that it is sufficient 
(multiple methods for locating LAR and multiple attempts), and if not, 
recommend additional steps be put in place. 
Once available after an EFIC enrollment, an LAR will be informed of 
the patient’s enrollment into the study and of the study details and 
potential risks and potential benefits of study participation.  At that 
time, the LAR will be given the option to continue participation in the 
study, or to cease participation then or at any time throughout the 
course of the study. If the LAR wants to continue participation, an 
informed consent process is performed and an informed consent form 
signed by the LAR will be obtained. If an established LAR has given 
consent for the participant to be enrolled, other family members' 
objections to inclusion will not result in the participant's removal from 









There is no specific 
requirement for how soon 
after an EFIC enrollment 
an LAR must be sought for 
consent to continue.  
Varied urgency may be 
explained by the extent of 
ongoing invasiveness of 
the intervention, by the 
level of risk, or by how 
practicable it may be to 
contact LARs early.  In 
general, notifying as early 
as possible increases 
transparency, but may not 
be appropriate in some 
trials, such as those of 
victims of cardiac arrest 
where most subjects die 
in the field and no study 
team is immediately 
activated at the time of 




participant will be asked to consent to or decline continued 
participation in the study.  If the participant wishes to continue and an 
LAR has not already provided consent and signed a consent form, the 
participant will sign an informed consent form.  If the LAR has already 
signed a consent form, an additional form signed by the participant is 
not required. 
Using the Informed Consent CRF, the study team will document 
efforts to find an LAR or other family member or surrogate.  This will 
include contact person (Subject, LAR, Other), number of attempts, 
date and time and outcome of attempts. The tracking process should 
continue until consent or withdrawal is obtained. The tracking process 
is complete once the LAR or participant has provided consent or has 
withdrawn.  It is expected that LAR consent or withdrawal be obtained 
within the first 24 hours, except in rare circumstances (no LAR 
identified, LAR not available, participant identification is unknown, 
participant expires prior to consent being obtained, etc.). 
For participants who expire prior to identifying an LAR or before LAR 
consent is obtained, consent should not be pursued further. However, 
once an LAR or family member is located, they should be informed of 
the subject’s participation.  The study team should document the 
notification conversation.  If it is not possible to have this notification 
conversation with the LAR or family of a deceased subject in the 
hospital, a “family notification letter for a deceased subject’’ should be 
used to notify the LAR or other family.  The template for this letter can 
be found in the “Toolbox” section of the sample TBI trial website.  A 
copy of the family notification letter (with return receipt) should be kept 
with the study documents. 
In the rare case where no LAR consent is obtained, the LAR is never 
available, and the participant remains incapable of consent at six 
months, documentation of the attempt process and condition of the 
participant will be recorded on the Informed Consent Log CRF.  In 








Tracking attempts to 
contact LARs is a best 










Even after attempts to 
contact an LAR or family 
member have ended, a 
note may be left in the 
medical record providing 
study team contact 
information in the event 
someone is eventually 
located.   
 
 
DESCRIPTION OF REFUSAL OF PARTICIPATION PROCEDURES 
(OPT-OUT) 
Individuals who learn about sample TBI trial and do not wish to 
participate may contact the trial investigators through the trial website, 
or by otherwise contacting a site study team or the CCC.  At their 
request, those declining to participate will be provided, prior to study 
start, an opt-out medical alert silicone bracelet that says “sample TBI 
trial declined” at no expense. Members of the public may also obtain 
and may wear this medical alert bracelet, or any other medical alert 
notification with the same message and be excluded from the trial 
without providing their name.  Wearing the provided bracelet or any 
other medical alert notification that says the name of the trial and the 
words “trial declined” is how the individual can communicate to the 
care team or study team, her/his wishes to opt out of the study in the 
event of a severe TBI.  The presence of a medical alert with the 
statement “sample TBI trial declined” is the metric for those with prior 
knowledge of the study to indicate their desire to opt out, which is an 
enrollment eligibility exclusion.    
 
DATA SAFETY MONITORING BOARD 
An independent Data Safety Monitoring Board (DSMB) has been 
established and has reviewed and approved the trial protocol.  The 
DSMB will oversee the course of the clinical trial.  The DSMB will 
provide ongoing evaluation of safety data as well as the overall 
conduct of the trial, as per institute guidelines.   
 
  
Although typical, opt-out 
mechanisms are not a 
regulatory requirement 
for EFIC trials.  Whether 
and how best to 
implement opt-out is 
likely to vary by trial and 
the nature of the 
enrollment.  Medical alert 
tags, bracelets, wallet 
cards, online or physical 
lists, medical record flags, 
and other options all have 
advantages and 
disadvantages to 
consider.  This may 
include burden on the 
potential subject, 
reliability and opportunity 
for error, protection of 
privacy and 
confidentiality, risk of 
misidentification, 
potential for stigma, or 
other complications. 
The value of opt-out 
seems to be primarily as a 
tool to allow those with 
objection to be heard and 
respected.  Given the 
mathematics of 
populations and study 
enrollment in most EFIC 
trials, opt-out may be 
more about giving these 
individuals voice, then 
about preventing the very 
low likelihood that they 
might be enrolled.    
Depending on the charter, 
a DSMB may or may not 
be involved in reviewing 
elements of EFIC.  Some 
FDA divisions request the 






Suggestions for Community Consultation Opportunities 
  
Meeting recruitment flyer 
Focus group moderator guide 
CC slide set - Full  
CC slide set - Reduced 
 
Letter to community physicians 
Letter to community members 
 
Survey Instruments 
Self-Administered Survey  
Self-Administered Survey – Additional languages 
Group Evaluation Survey  
Telephone Survey  
 
PD Material 
Suggestions for Public Disclosure Opportunities  
 
Website and Video Content 
Trial-specific Video/Public Service Announcement (6 seconds) 
Trial-specific Video/Public Service Announcement (15 seconds)  
Emergency Research Video Scripts – Non-trial specific  




Brochure – Additional languages 
AD/Flyer/Poster 
AD/Flyer/Poster – Additional languages 
 
Opt-out Material 
Opt-out bracelet request form  
Opt-out bracelet mailing letter  
 
 
Additional EFIC Material  
Letter to notify families or LAR about EFIC enrollment in subjects who die 




This APPENDIX lists the 
kinds of trial specific 
community consultation 
and public disclosure 
materials that are created 
and provided as central 
resources for all 
participating sites.  This 
would be pre-approved by 
the CIRB at the time of 
protocol review, and the 
unmodified content of 
these used by sites 
without further approval.  
If sites develop additional 
new and valuable 
materials, the CCC would 
send these to the CIRB for 
review prior to their use 
by the site.  When 
approved, new materials 
are added to the list for 
subsequent use by any 
site. 
 
Because these materials 
can be dynamic, the links 
on this page have been 
disabled.  The list is 
included here only as an 
example of the kinds of 




B. Standard Operating Procedure for Trial Applications involving Exception from 
Informed Consent (EFIC) to a Single/Central Institutional Review Board 
 
Purpose  
Our goals for this procedure are to protect the interests of human 
research participants to be enrolled in emergency research trials with 
EFIC, to respect the communities from which participants will be 
enrolled, to comply with applicable regulations and their intent, and to 
create efficiencies for both the IRB and the applicants. 
 
Definitions   
The following are operational definitions for the purposes of this 
procedure  
CC/PD refers to Community Consultation and Public Disclosure 
activities as described at 21 CFR 50.24 
CCC refers to the investigators’ Clinical Coordinating Center for the 
trial 
IRB-IS  refers to the web based IRB information system 
DCC refers to the investigators’ Data Coordinating Center for the 
trial     
DSMB refers to the trial-specific Data Safety Monitoring Board 
EFIC  refers to emergency research conducted with exception from 
informed consent as regulated primarily under FDA 
regulations 21 CFR 50.24.  EFIC also refers to research 
conducted under 45 CFR 46.101(i) when consistent with the 
HHS Secretarial Waiver from October 2, 1996 -- Notice, HHS, 
Informed Consent Exemption for Emergency Research   
CIRB refers to the Central Institutional Review Board reviewing the 
application 
FDA the United States Food and Drug Administration 
IND Investigational New Drug application 
IDE Investigational Device Exemption application 
CTMS  refers to a comprehensive Clinical Trial Management System  
 
Procedures 
A. FDA approval of IND or IDE identifying the plan to conduct a trial 
using EFIC.   
For EFIC research regulated by FDA, the sponsor will obtain 
approval for an IND or IDE prior to submitting an IRB application.  
For EFIC research not regulated by FDA, the investigators should 




concordant with this determination.  Creation and review of an IRB 
application may proceed while the IND/IDE is on clinical hold if the 
reasons for the clinical hold do not contain concerns related to the 
protection of human research participants. 
B. DSMB approval.  
The applicants will present the study protocol and consent form to 
the study DSMB for comment, suggestions, and approval before 
submission to the ER-CIRB. 
C. Protocol (Parent) application submission to ER-CIRB. 
The applicant will submit an IRB protocol application that also 
includes an EFIC plan into IRB-IS.  The EFIC plan will be 
submitted as “Additional Documentation”.  The EFIC plan will 
include the following; 
a. Itemized descriptions of how the trial meets each required 
qualification for EFIC described at 21 CFR 50.24 
b. Menu of community consultation event types and a plan for a 
minimum required mix of events 
c. Menu of public disclosure activities and a plan for a minimum 
required mix of activities 
d. Check off list for disease-based and geographic-based 
communities of special interest that will be engaged 
e. Templates for materials to be used for community consultation 
and public disclosure 
D. ER-CIRB review of protocol application. 
The ER-CIRB will review the study protocol, consent form, and 
EFIC plan.  If the ER-CIRB identifies concerns or requires 
modifications, the investigators will revise the application as 
needed.  If the protocol, consent form, and EFIC plans are 
acceptable, the ER-CIRB will approve the protocol application.  No 
CC/PD will be conducted until approval of the protocol application 
and EFIC plan. 
E. Sites prepare individual CC/PD plans. 
Sites use the IRB approved menus and the IRB approved required 
mix of events (from the protocol application) to develop lists of 
proposed individual CC/PD events and activities. The CCC 
oversees and assists sites throughout this site development 
process.  
a. The site plan includes a log of proposed CC/PD events and 
activities, including planned dates and intended communities to 
The FDA “may proceed” 
determination is required 










Site plans include 
enhanced local context 
information including 
local demographics, 
practice patterns, and 
relevant aspects of local 
culture.  This should be 
similar to, but more 
complete, than the local 
context form completed 
for other non-EFIC trials. 
 
 
be engaged.  These events and activities are entered into 
CTMS.  The ER-CIRB will also have access to these event logs 
in the CTMS. 
b. The site plan includes a supplemental EFIC local context form 
that will also be completed in the CTMS with additional 
information about communities served by the institution.   
c. If sites develop new materials for use in CC/PD these must be 
submitted to the sponsor, via the CCC.  The CCC will submit 
any additional sponsor approved material to the ER-CIRB 
through IRB-IS via an amendment to the protocol application 
for review and approval prior to their use.   
d. The ER-CIRB will have continuous access to the site plan (the 
CC/PD event logs and supplemental EFIC local context form) in 
CTMS throughout the conduct of CC/PD. 
F. Sites perform CC/PD activities and events. 
a. Sites commence the CC/PD activities and events they have 
listed in the log.  As activities and events are completed, event 
forms are completed in CTMS.  
b. If activities and events are rescheduled or replaced with new 
events, these changes are immediately logged in CTMS.  In 
this way, site progress may be checked by the CCC or the ER-
CIRB at any time.   
c. Representatives of the CCC or the ER-CIRB may also use the 
log to plan their own visits to site CC/PD activities and events at 
their discretion.     
G. Site application submission to the ER-CIRB. 
Sites submit all information for their site CIRB applications in 
CTMS, including any revisions to the EFIC local context form.  
After a site has completed its CC/PD and submitted all findings 
and summaries to CTMS, these are reviewed by the CCC and a 
report of findings is prepared to include as additional documents 
with the site ER-CIRB application.  The CCC then submits the site 
application to the ER-CIRB through IRB-IS.  Click for example of a 
site-specific CCC activities report. 
 
H. ER-CIRB review of site applications. 
The ER-CIRB does an explicit review of each site application 
including discussion of each site-specific CC/PD report.  The ER-
CIRB may use a checklist to aid in the review of each site.  
Specifically, the IRB will check if the site’s completed activities 
complied with the menu and requirements in the IRB approved 
It is important for the CCC 
to oversee the site plans 
to ensure that sites are 
complying with the overall 
EFIC plan to maximize the 
opportunity for site 
applications to be 
approvable in a single 
review by the ER-CIRB. 
Through accumulated 
experience across trials 
and across sites, the CCC 
is best situated to help 
sites benefit from shared 
resources and peer-to-
peer learning. 
An alternative strategy is 
to have the ER-CIRB also 
review each site plan prior 
to the site initiating 
CC/PD.  These may help 
clarify expectations and 
decrease the risk that the 
IRB will have to defer a 
subsequent site 
application and ask the 
site for additional 
activities after the site 
approval review meeting.  
The trade-off is that this 
extra approval step for all 
sites doubles the number 
of reviews, potentially 
decreasing the efficiency 
of both the IRB and the 
sites and delaying study 




EFIC plan in the protocol application, if the completed activities 
reflect a sufficient portion of the spectrum of community described 
in the sites local context form, if the CC/PD performed represent 
sufficient engagement and notification of the communities, and if 
any of the findings reported indicate a need for additional follow up 
CC/PD.  If the site application and EFIC reports are acceptable, 
the site may be approved by the ER-CIRB and permitted to begin 
enrollment.  Site applications may be reviewed as rapidly as 
submitted or may be batched at the discretion of the ER-CIRB. 
I. Reporting to the public. 
Cumulative reports of CC/PD will be assembled by the CCC and 
reported to the FDA docket at least annually until all pre-trial 
CC/PD are completed.  An additional report of post-trial public 
disclosure activities will be assembled by the CCC and to the FDA 
docket after the trial is completed.  If the trial is not FDA regulated, 
the same materials will be posted on another public facing web-
page. 
J. Reporting to relying institutions.   
Sites will be able to download their own CC/PD findings report 
from CTMS and may use these to report to their own relying 
institution if their institution requests to review these internally, but 
this is not required.  Similarly, the ER-CIRB will provide minutes of 
the review of the site application to the CCC to provide to the 
relying site if requested.  Institutions that wish to share with the 
CIRB any findings or additional local context beyond that already 
provided by the investigators are welcome to do so within the site 
application. 
K. Protocol application close out. 
At the end of the clinical trial, all sites will report all required post-
trial public disclosure activities in CTMS.  The CCC will prepare a 
cumulative report of all post trial public disclosure activities at all 
sites, which will be submitted to the ER-CIRB with the protocol 





Post-trial PD reported to 
the FDA docket must 
include study results and 
demographics of the 
participants. 
 
Although not required, 
relying institutions may 
opt for varying levels of 
internal review by some 
part of their human 
research protection 
program (HRPP), that may 
or may not involve the IRB 
itself.  Institutional HRPPs 
may wish to contribute 
additional local context to 
the CIRB beyond that 
already provided by the 
investigators.  This can be 
provided as a letter or 
memo supplementing the 
site application, via the 
investigators, the sponsor, 
or by direct 
communication between 
the IRBs.   
 
 
C. Process Guideline for Central IRB Review of Site Applications for EFIC Trials:  
How to Review Local Community Consultation and Public Disclosure Findings 
  
This document is intended to provide advice to central IRB panels on 
potential processes they might use to guide and manage deliberations 
related to local context for site applications of clinical trials involving 
exception from informed consent (EFIC) for emergency research.  The 
document is informed by observations of IRB deliberations of EFIC-
related community consultations and public disclosure and a related 
stakeholder workshop conducted as part of an empirical ethics grant 
from the NIH Office of the Director.  In addition to this qualitative 
research, this document is also informed by the cumulative 
experiences and views of the investigators.  The document is meant to 
suggest a framework to aid in efficiency and effectiveness of the 
review, but is not intended to constrain IRB consideration or 
discussion in any way. 
Review of the trial EFIC plan in the protocol application 
Prior to review of site applications for a trial involving EFIC, the IRB 
should briefly re-cap the trial-specific EFIC plan proposed with the 
previously approved protocol application.  This allows the panel 
members to re-familiarize themselves with the quantitative and 
qualitative expectations of sites.  These expectations describe the site 
self-assessments and reporting of important elements of their own 
local context, and the number and types of community consultation 
and public disclosure activities to be completed.  The plan also 
describes the underlying goals of community consultation and public 
disclosure as contextualized for the application. At the IRB meeting, 
the IRB chair or other designated reviewer or member should be 
assigned to present the key elements of the plan to the full board. 
Community consultation / public disclosure site report format 
Site applications for clinical trials involving EFIC will be accompanied 
by a consistently formatted report summarizing the community 
consultation and public disclosure activities performed by the site.  
The report format presents a brief narrative summary and aggregated 
data at the front, and then many more pages of granular listings of 
individual comments in the rest of the report.  At the time of the first 
site application to be reviewed by the panel, prior to deliberation of the 
reports content and the site application, the IRB chair or other 
designated reviewer or member should briefly orient the full board to 











Evaluation of both the 
aggregate and the source 
data is helpful.  Coding of 
open-ended comments as 
indicating ‘support’ or 
‘concern’ is subjective.  
The ER-CIRB has noted 
that sites often designate 
neutral comments as 
‘concerns’ in an over-




Deliberation - quantitative consideration 
During the discussion and deliberation of each site application, a 
systematic approach to the review of local context requirements may 
start with quantitative aspects of the site community consultation / 
public disclosure report.  The trial EFIC plan requires a specific 
number of activities in more than one category of activity types.  The 
IRB should confirm that these requirements have been met.  Site 
applications failing to meet these criteria may be tabled and the site 
queried prior to further review, or the review may continue but the site 
application not approved until the deficiency is addressed. 
The panel may also want to consider quantitative aspects of the 
community consultation / public disclosure report that do not have pre-
defined requirements, but may be salient.  The IRB may wish to 
consider the number of activities performed at each site, the number 
of participants in each event, and the number of open-ended 
comments or closed-ended responses collected and reported.  There 
are no required numerical criteria for these aspects because they are 
expected to differ from site to site based on the nature of the activities 
performed.  For example, sites performing in depth focus groups may 
have fewer participants but more feedback, while those hosting a 
booth at the state fair may have far more participants but briefer 
contact and fewer recorded responses from each.  In the absence of 
objective criteria, the panel members should evaluate these 
quantitative aspects subjectively.  Panel members may consider these 
metrics in the context of the numbers they might expect based on the 
type of activities reported, or in comparison to the numbers reported at 
other sites.  In comparing to other sites, the panel should keep in mind 
that there will always be a range and that all sites cannot be above 
average.  
Deliberation – qualitative considerations 
The panel then should consider qualitative aspects of the community 
consultation / public disclosure report.  First, the panel should consider 
whether the activities performed by the site are appropriately aligned 
with, and sufficiently address, the principals and goals established for 
community consultation and public disclosure in the trial-specific EFIC 
plan.  For example, is there evidence for respect for community, for 
two-way communication in consultations, for transparency in public 
disclosures?  The site report should be demonstrative of how 
principals and goals were considered. 
Consideration may be given to whether a variety of types of 
stakeholders participated in the site’s activities.  Were both geographic 
and disease-related communities consulted?  While it is impracticable 
Centralized review of EFIC 
applications by a single 
IRB offers a new 
opportunity to see and 
compare site CC/PD in 
ways that local IRBs do 
not.   
The CIRB needs to be 
aware that sites in the 
same city or region are 
encouraged to work 
together on CC/PD and 
their applications may 
include duplicated events 
and findings.  These 
should be clearly 
designated in site 
applications.  The IRB may 
wish to make sure that 
there is sufficient 
engagement by both sites 
to meet the stated 
principles of CC/PD. 
Comparing sites 
applications can be 
helpful to the extent that 
it may provide the IRB a 
better cumulative 
understanding of 
community attitudes that 
are likely similar between 
locales.  However, the IRB 
should try to maintain 
consistent standards for 
sufficient CC/PD, and not 
allow having seen better 
and worse prior site 
applications to raise or 
lower the bar over time. 
 
 
to reach all demographics in a representative manner, the panel 
should consider the diversity achieved in the events conducted.  The 
panel may consider whether any parts of the community with 
increased stakes or special interest in the research have been 
adequately consulted.  The diversity of community may be considered 
by the IRB in the context of the site’s self-reported local context report, 
or by comparison with other sites.  
Other qualitative assessments of the community consultation / public 
disclosure findings include consideration of the closed-ended and 
open-ended feedback from participants in the site’s activities.  While 
EFIC is explicitly not a community consent process, the degree of 
support or concern expressed in these responses can be considered 
in the context of similar findings from the literature and the FDA EFIC 
docket for previous EFIC trials, or comparing different communities.  
The IRB may also consider the nature of specific concerns and any of 
these should preclude site participation or be otherwise addressed.  
Other elements of local context review 
Before completing the deliberation of community consultation and 
public disclosure the panel should review and consider other elements 
of local context review.  Site self-reporting of local context issues 
related to the community served, past relevant experiences with EFIC 
or emergency research at the site, local regulations or laws impacting 
the research, local medical practice patterns intersecting with the trial 
should all be considered if they may affect the protection of human 
subjects.  Local IRB or other elements of the local institutional 
research administration also have the option of submitting information 
relating to local context as well.  If submitted, such optional 
information should be considered and discussed at this point in the 
site review. 
Board actions 
These considerations of site applications for clinical trials involving 
EFIC are supplemental to the standard elements of site application 
review by the IRB.  Approval based on deliberation of community 
consultation and public disclosure is incorporated into the IRB 
approval of the site application. 
Queries, contingencies, or non-approval based on review of 
community consultation / public disclosure activities should be 
reported back to the sites as specifically as possible.  Clear and 
explicit descriptions of any additional activities desired, or 
modifications of the application required, are necessary to rapidly 
providing the panel with any necessary corrective actions. 
Qualitative evaluations 
may consider numerous 
parameters including the 
numbers of activities, 
attendees, respondents, 
or responses.   
Diversity can be manifest 
through events that draw 
diverse participation.  In 
this case, the narrative 
description of the activity 
should indicate whether 
interactions at the event 
involved the breadth of 
their diversity.  
Alternatively, each event 
may be focused on a 
narrow slice of the 
community, and diversity 
is obtained by the variety 
of these focused events.  
IRBs may wish to 
emphasize key subgroups 
including those that are 
historically underserved, 




Centralized review of clinical trials involving EFIC is new.  It is 
expected that the IRB and the investigators at both the Clinical 
Coordinating Center and the sites will identify ways to improve the 
content and the process over time.  Mechanisms for incorporating 
these lessons back into systematic improvements will be pursued and 






Supplemental Material:  Site EFIC Activity Reports for IRB Submission 
The following sections describe a possible layout and organization of content of the reports of site EFIC 
activities prepared for submission to the IRB as part of the IRB’s site review process.  A complete sample site 
submission is also provided.  The report layout has parts for Community Consultation Public Disclosure.   
The first 2 pages of the 
Community Consultation section 
provides a high level summary of 
activities and feedback from the 
community. 
Next is a narrative 
explaining how the site met 
the goals of the EFIC plan 
and what the site learned 
and experienced. 
 A table listing CC 
events follows, and then 
a few pages with brief 
narrative descriptions of 
what each event was, 
and what it was like. 
 Quantitative results of 
closed ended surveys are 
shown next with graphical 
visualization of the data. 
 Qualitative listings of 
all open-ended community 
feedback is finally included 




The first 2 pages of the 
Public Disclosure section 
provides a high level summary 
of categories of activities. 
 A table follows that lists each 
individual PD activity performed 
along with the audience reached 
and the nature of the disclosure.  
 The next several pages 
include images of the actual 
visual and print disclosures 
used including brochures, 
advertisements, or 
screenshots as appropriate. 
 The last page of the 
report includes answers to 
EFIC related local context 
questions requested by 
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